The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
EMA Committee for Medicinal Products for Human Use (CHMP) has adopted a negative opinion on the marketing authorization approval (MAA) for the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab). 26 July 2024
Belgian clinical-stage G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the closing of a 60 million euros Series B financing 26 July 2024
US clinical-stage biotech Immunome has announced exclusive license agreement with Israel-based Nectin Therapeutics for rights to a panel of antibodies targeting an undisclosed target. 26 July 2024
Zymeworks has appointed Leone Patterson as executive vice president, and chief business and financial officer, effective September 1, 2024. 26 July 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024